JP2006508979A5 - - Google Patents

Download PDF

Info

Publication number
JP2006508979A5
JP2006508979A5 JP2004553551A JP2004553551A JP2006508979A5 JP 2006508979 A5 JP2006508979 A5 JP 2006508979A5 JP 2004553551 A JP2004553551 A JP 2004553551A JP 2004553551 A JP2004553551 A JP 2004553551A JP 2006508979 A5 JP2006508979 A5 JP 2006508979A5
Authority
JP
Japan
Prior art keywords
heteroaryl
aryl
heterocyclyl
arylalkyl
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2004553551A
Other languages
English (en)
Japanese (ja)
Other versions
JP4611745B2 (ja
JP2006508979A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2003/035670 external-priority patent/WO2004046101A2/en
Publication of JP2006508979A publication Critical patent/JP2006508979A/ja
Publication of JP2006508979A5 publication Critical patent/JP2006508979A5/ja
Application granted granted Critical
Publication of JP4611745B2 publication Critical patent/JP4611745B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2004553551A 2002-11-20 2003-11-10 ErbB2及びEGFR阻害剤としてのシアノグアニジン及びシアノアミジン Expired - Fee Related JP4611745B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42754402P 2002-11-20 2002-11-20
PCT/US2003/035670 WO2004046101A2 (en) 2002-11-20 2003-11-10 Cyanoguanidines and cyanoamidines as erbb2 and egfr inhibitors

Publications (3)

Publication Number Publication Date
JP2006508979A JP2006508979A (ja) 2006-03-16
JP2006508979A5 true JP2006508979A5 (enExample) 2006-08-03
JP4611745B2 JP4611745B2 (ja) 2011-01-12

Family

ID=32326558

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004553551A Expired - Fee Related JP4611745B2 (ja) 2002-11-20 2003-11-10 ErbB2及びEGFR阻害剤としてのシアノグアニジン及びシアノアミジン

Country Status (6)

Country Link
EP (1) EP1567506A4 (enExample)
JP (1) JP4611745B2 (enExample)
AU (1) AU2003291394B2 (enExample)
CA (1) CA2506503A1 (enExample)
NZ (1) NZ540092A (enExample)
WO (1) WO2004046101A2 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6562319B2 (en) 2001-03-12 2003-05-13 Yissum Research Development Company Of The Hebrew University Of Jerusalem Radiolabeled irreversible inhibitors of epidermal growth factor receptor tyrosine kinase and their use in radioimaging and radiotherapy
CA2536140A1 (en) * 2003-08-18 2005-02-24 Pfizer Products Inc. Dosing schedule for erbb2 anticancer agents
AU2004270016A1 (en) * 2003-09-11 2005-03-17 Hadasit Medical Research Services And Development Ltd. Radiolabeled anilinoquinazolines and their use in radioimaging and radiotherapy
GB0326459D0 (en) 2003-11-13 2003-12-17 Astrazeneca Ab Quinazoline derivatives
JP2008513463A (ja) 2004-09-15 2008-05-01 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ チアゾロピリジンキナーゼ阻害剤
US7579356B2 (en) 2005-05-04 2009-08-25 Janssen Pharmaceutica Nv Thia-tetraazaacenaphthylene kinase inhibitors
DE102006012251A1 (de) * 2006-03-15 2007-11-08 Grünenthal GmbH Substituierte 4-Amino-chinazolin-Derivate und ihre Verwendung zur Herstellung von Arzneimitteln
CL2007003158A1 (es) 2006-11-02 2008-05-16 Astrazeneca Ab Procedimiento de preparacion de compuestos derivados de quinazolina o sus sales farmaceuticamente aceptables; compuestos intermediarios; procedimiento de preparacion.
US8080558B2 (en) 2007-10-29 2011-12-20 Natco Pharma Limited 4-(tetrazol-5-yl)-quinazoline derivatives as anti-cancer agent
EP2448409A4 (en) * 2009-07-02 2013-04-10 Newgen Therapeutics Inc PHOSPHOROUS CHINAZOLIN COMPOUNDS AND METHOD OF USE THEREOF
EP2956138B1 (en) 2013-02-15 2022-06-22 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
US9688688B2 (en) 2013-02-20 2017-06-27 Kala Pharmaceuticals, Inc. Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
MX368903B (es) 2013-02-20 2019-10-21 Kala Pharmaceuticals Inc Compuestos terapéuticos y sus usos en el tratamiento de enfermedades proliferativas.
US9890173B2 (en) 2013-11-01 2018-02-13 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
US9458169B2 (en) 2013-11-01 2016-10-04 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
WO2017122205A1 (en) 2016-01-13 2017-07-20 Hadasit Medical Research Services And Development Ltd. Radiolabeled erlotinib analogs and uses thereof
EP3509423A4 (en) 2016-09-08 2020-05-13 Kala Pharmaceuticals, Inc. CRYSTALLINE FORMS OF THERAPEUTIC COMPOUNDS AND USES THEREOF
US10336767B2 (en) 2016-09-08 2019-07-02 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
AU2017324713B2 (en) 2016-09-08 2020-08-13 KALA BIO, Inc. Crystalline forms of therapeutic compounds and uses thereof
CN108285421A (zh) * 2018-01-26 2018-07-17 黑龙江鑫创生物科技开发有限公司 一种微通道反应器合成拉帕替尼中间体的方法
AU2020397821B2 (en) * 2019-12-02 2024-07-25 Academia Sinica PDIA4 inhibitors and use thereof for inhibiting ß-cell pathogenesis and treating diabetes

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69536015D1 (de) 1995-03-30 2009-12-10 Pfizer Prod Inc Chinazolinone Derivate
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
DE69720965T2 (de) * 1996-02-13 2004-02-05 Astrazeneca Ab Chinazolinderivate und deren verwendung als vegf hemmer
HRP970371A2 (en) 1996-07-13 1998-08-31 Kathryn Jane Smith Heterocyclic compounds
EP1067123B1 (en) * 1998-03-31 2011-01-19 Kyowa Hakko Kirin Co., Ltd. Nitrogenous heterocyclic compounds
GB2345486A (en) 1999-01-11 2000-07-12 Glaxo Group Ltd Heteroaromatic protein tyrosine kinase inhibitors
UA71945C2 (en) 1999-01-27 2005-01-17 Pfizer Prod Inc Substituted bicyclic derivatives being used as anticancer agents
EP1292591B1 (en) 2000-06-22 2005-02-02 Pfizer Products Inc. Substituted bicyclic derivatives for the treatment of abnormal cell growth

Similar Documents

Publication Publication Date Title
JP2006508979A5 (enExample)
JP2009515988A5 (enExample)
JP2005526076A5 (enExample)
JP2006502119A5 (enExample)
JP2008510828A5 (enExample)
JP2010535722A5 (enExample)
JP2010507602A5 (enExample)
JP2013504593A5 (enExample)
JP2011513410A5 (enExample)
JP2007502295A5 (enExample)
JP2010511721A5 (enExample)
JP2005508905A5 (enExample)
JP2019513778A5 (enExample)
JP2007524696A5 (enExample)
JP2016535769A5 (enExample)
JP2007523139A5 (enExample)
JP2010501478A5 (enExample)
JP2008523069A5 (enExample)
JP2002512243A5 (enExample)
JP2009534468A5 (enExample)
JP2009533410A5 (enExample)
JP2006514691A5 (enExample)
JP2009537469A5 (enExample)
JP2010077137A5 (enExample)
JP2005535586A5 (enExample)